Douglas Weckstein

2.9k total citations
24 papers, 1.3k citations indexed

About

Douglas Weckstein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Douglas Weckstein has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Douglas Weckstein's work include Colorectal Cancer Treatments and Studies (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Douglas Weckstein is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Douglas Weckstein collaborates with scholars based in United States, Switzerland and Spain. Douglas Weckstein's co-authors include Constance Cirrincione, William T. Barry, Eric P. Winer, Clifford A. Hudis, Charles L. Shapiro, Ian E. Krop, Lisa A. Carey, Charles M. Perou, N. Lynn Henry and David W. Ollila and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Douglas Weckstein

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Weckstein United States	15	780	397	295	281	253	24	1.3k
Blair Egerdie Canada	15	916 1.2×	712 1.8×	115 0.4×	257 0.9×	306 1.2×	31	1.7k
John Hohneker United States	23	1.5k 1.9×	496 1.2×	263 0.9×	171 0.6×	290 1.1×	40	1.9k
B. Massidda Italy	23	1.6k 2.1×	848 2.1×	662 2.2×	49 0.2×	302 1.2×	84	2.3k
Jaya Ghosh India	18	563 0.7×	284 0.7×	177 0.6×	133 0.5×	198 0.8×	102	1.5k
Jindřich Fínek Czechia	23	874 1.1×	607 1.5×	402 1.4×	146 0.5×	368 1.5×	161	1.5k
V. Servent France	12	610 0.8×	352 0.9×	304 1.0×	213 0.8×	95 0.4×	30	1.2k
Philip J. Saylor United States	25	1.0k 1.3×	1.2k 2.9×	393 1.3×	326 1.2×	492 1.9×	82	2.5k
Aline Guillot France	16	315 0.4×	692 1.7×	330 1.1×	132 0.5×	426 1.7×	62	1.0k
Linda Coate Ireland	13	333 0.4×	343 0.9×	140 0.5×	105 0.4×	161 0.6×	36	756
Re G Italy	20	823 1.1×	576 1.5×	169 0.6×	49 0.2×	513 2.0×	96	1.6k

Countries citing papers authored by Douglas Weckstein

Since Specialization

Citations

This map shows the geographic impact of Douglas Weckstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Weckstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Weckstein more than expected).

Fields of papers citing papers by Douglas Weckstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Weckstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Weckstein. The network helps show where Douglas Weckstein may publish in the future.

Co-authorship network of co-authors of Douglas Weckstein

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Weckstein. A scholar is included among the top collaborators of Douglas Weckstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Weckstein. Douglas Weckstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aggarwal, Rahul, Glenn Heller, David W. Hillman, et al.. (2023). Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).. Journal of Clinical Oncology. 41(6_suppl). 208–208. 3 indexed citations

Lipsyc-Sharf, Marla, Fang‐Shu Ou, Matthew B. Yurgelun, et al.. (2022). Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. The Oncologist. 27(4). 292–298. 7 indexed citations

Lipsyc-Sharf, Marla, Fang‐Shu Ou, Matthew B. Yurgelun, et al.. (2020). Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. Journal of Clinical Oncology. 38(4_suppl). 102–102. 1 indexed citations

Aggarwal, Rahul, Scott E. Eggener, Ronald C. Chen, et al.. (2018). A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).. Journal of Clinical Oncology. 36(15_suppl). TPS5090–TPS5090. 5 indexed citations

Ng, Kimmie, Halla Nimeiri, Nadine J. McCleary, et al.. (2017). SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.. Journal of Clinical Oncology. 35(15_suppl). 3506–3506. 16 indexed citations

Carey, Lisa A., Donald A. Berry, Constance Cirrincione, et al.. (2015). Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology. 34(6). 542–549. 263 indexed citations

Ades, Steven, Shailesh Kumar, Murad Alam, et al.. (2015). Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. Journal of Thrombosis and Haemostasis. 13(6). 998–1003. 63 indexed citations

Himelstein, Andrew L., Rui Qin, Paul J. Novotny, et al.. (2015). CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.. Journal of Clinical Oncology. 33(15_suppl). 9501–9501. 14 indexed citations

Lin, Nancy U., Davinia Seah, Rebecca Gelman, et al.. (2013). A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 139(2). 403–410. 15 indexed citations

10.

Carey, Lisa A., Donald A. Berry, David W. Ollila, et al.. (2013). Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 500–500. 47 indexed citations

11.

Nakabayashi, Mari, Kevin D. Courtney, Geoffrey Buckle, et al.. (2012). Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer. British Journal of Urology. 110(11). 1729–1735. 62 indexed citations

12.

Shapiro, Charles L., Susan Halabi, Vera Hárs, et al.. (2011). Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. European Journal of Cancer. 47(5). 683–689. 81 indexed citations

13.

Weckstein, Douglas, et al.. (2011). Assessment of Perceived Cost to the Patient and Other Barriers to Clinical Trial Participation. Journal of Oncology Practice. 7(5). 330–333. 26 indexed citations

14.

Hurria, Arti, Constance Cirrincione, Hyman B. Muss, et al.. (2011). Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. Journal of Clinical Oncology. 29(10). 1290–1296. 265 indexed citations

15.

Weckstein, Douglas, et al.. (2010). The assessment of cost and other barriers to patient clinical trial participation in the community setting.. Journal of Clinical Oncology. 28(15_suppl). 6030–6030. 1 indexed citations

16.

Buckle, Geoffrey, Lillian Werner, William Oh, et al.. (2010). Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC).. Journal of Clinical Oncology. 28(15_suppl). 4660–4660. 2 indexed citations

17.

Sonpavde, Guru, Phillip Periman, Douglas Weckstein, et al.. (2009). Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology. 21(2). 319–324. 115 indexed citations

18.

Periman, Phillip, Guru Sonpavde, Douglas Weckstein, et al.. (2008). Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 5157–5157. 12 indexed citations

19.

Gibson, Raymond E., Douglas Weckstein, Elaine M. Jagoda, et al.. (1984). The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro.. PubMed. 25(2). 214–22. 47 indexed citations

20.

Gibson, Raymond E., Waclaw J. Rzeszotarski, William C. Eckelman, et al.. (1983). Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors. Biochemical Pharmacology. 32(12). 1851–1856. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact